Liposarcoma future or investigational therapies: Difference between revisions
No edit summary |
(Mahshid) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 36: | Line 36: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 02:16, 27 November 2017
|
Liposarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Liposarcoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Liposarcoma future or investigational therapies |
|
Risk calculators and risk factors for Liposarcoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Current clinical trials of liposarcoma are promising and genetic basis of the disease is studied extensively to find an effective treatment for this disease.
Future or Investigational Therapies
Clinical trials
Tests and treatment go through four different phases of clinical trail to test the benefits of it. The four phases of treatment are as follows.[1]
- Phase 1 trial
It aims to find out the best dose of a new drug with the lowest side effects
- Phase 2 trial
Asses whether a drug works for a specific cancer or not
- Phase 3 trial
Compares a new drug to a standard treatment
- Phase 4 trail
It involves drugs already approved by US FDA (Food and Drug administration) for atleast one disease.
SARC trials
Clinical trails are being conducted by SARC on soft tissue tumors as a part of furute investigationa therapies.[2]
23andMe research project
They work with the patient community to find the genetic markers of sarcoma. [3]